Citations

Clear

3138 citation(s) found for "Smith, AM".

Epigenetic Markers of Renal Function in African Americans
Bomotti, Samantha , Smith, Jennifer A. , Zagel, Alicia , Kardia, Sharon L. R., Turner, Stephen T. , Taylor, Jacquelyn Y. , Smith, Jennifer A

Mayo Clinic

Nursing Research and Practice | December 12, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-9

10.1155/2013/687519 | PMID 24396594 Get It

Chronic kidney disease (CKD) is an increasing concern in the United States due to its rapidly rising prevalence, particularly among African Americans. Epigenetic DNA methylation markers are becoming important biomarkers of chronic diseases such as CKD. To better understand how these methylation markers play a role in kidney function, we measured 26,428 DNA methylation sites in 972 African Americans from the Genetic Epidemiology Network of Arteriopathy (GENOA) study. We then evaluated (1) whether epigenetic markers are associated with estimated glomerular filtration rate (eGFR), (2) whether the significantly associated markers are also associated with traditional risk factors and/or novel biomarkers for eGFR, and (3) how much additional variation in eGFR is explained by epigenetic markers beyond established risk factors and biomarkers. The majority of methylation markers most significantly associated with eGFR (24 out of the top 30) appeared to function, at least in part, through pathways related to aging, inflammation, or cholesterol. However, six epigenetic markers were still able to significantly predict eGFR after adjustment for other risk factors. This work shows that epigenetic markers may offer valuable new insight into the complex pathophysiology of CKD in African Americans.
Nanoparticles for Combination Drug Therapy
Ma, Liang , Smith, Andrew M. , Kohli, Manish , Smith, A M

Mayo Clinic

ACS Nano | November 26, 2013 | Volume: 7 | Issue: 11 | Pages: 9518-9525

10.1021/nn405674m | PMID 24274814 Get It

Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease
Belcher, John D. , Chen, Chunsheng , Nguyen, Julia , Milbauer, Liming , Abdulla, Fuad , Alayash, Abdu I. , Smith, Ann , Nath, Karl A. , Hebbel, Robert P. , Vercellotti, Gregory M.

Mayo Clinic

Blood | November 26, 2013 | Volume: 123 | Issue: 3 | Pages: 377-390

10.1182/blood-2013-04-495887 | PMID 24277079 Get It

Key Points Heme, released from hemoglobin, elicits vaso-occlusion in transgenic sickle mice via endothelial TLR4 signaling. Heme/TLR4 signaling activates NF-κB and triggers vaso-occlusion through Weibel-Palade body degranulation and adhesion molecule expression.
Clinical features and long‐term prognosis of trochlear headaches
Garrity, J. A., Boes, CJ, Smith, Jonathan H.

Mayo Clinic

European Journal of Neurology | November 23, 2013 | Volume: 21 | Issue: 4 | Pages: 577-585

10.1111/ene.12312 | PMID 24261483 Get It

Background and purposeTrochlear headaches are a recently recognized cause of headache, of which both primary and inflammatory subtypes are recognized. The clinical features, long‐term prognosis and optimal treatment strategy have not been well defined.MethodsA cohort of 25 patients with trochlear headache seen at the Mayo Clinic between 10 July 2007 and 28 June 2012 were identified.ResultsThe diagnosis of trochlear headache was not recognized by the referring neurologist or ophthalmologist in any case. Patients most often presented with a new daily from onset headache (n = 22, 88%). The most characteristic headache syndrome was reported as continuous, achy, periorbital pain associated with photophobia and aggravation by eye movement, especially reading. Individuals with a prior history of migraine were likely to have associated nausea and experience trochlear migraine. Amongst individuals with trochleitis, 5/12 (41.6%) had an identified secondary mechanism. Treatment responses were generally, but not invariably, favorable to dexamethasone/lidocaine injections near the trochlea. At a median follow‐up of 34 months (range 0–68), 10/25 (40%) of the cohort had experienced complete remission.ConclusionsTrochlear headaches are poorly recognized, have characteristic clinical features, and often require serial injections to optimize the treatment outcome. The identification of trochleitis should prompt neuroimaging to look for a secondary cause.
Double‐blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma
Grivas, Petros , Daignault, Stephanie, Tagawa, Scott T. , Nanus, David M. , Petrylak, Daniel P. , Vaughn, David J. , Bylow, Kathryn, Wong, Steven, Keller, Evan T. , Al‐Hawary, Mahmoud, Smith, David C. , Hussain, Maha , Stadler, Walter M. , Dreicer, Robert , Kohli, Manish , Sottnik, Joseph L. , Tagawa, Scott T , Hussain, Maha H A

Mayo Clinic

Cancer | November 18, 2013 | Volume: 120 | Issue: 5 | Pages: 692-701

10.1002/cncr.28477 | PMID 24249435 Get It

BACKGROUNDAngiogenesis contributes to the progression of urothelial carcinoma (UC). In the current study, the authors investigated the role of maintenance sunitinib in patients with advanced UC.METHODSPatients with locally recurrent/metastatic UC and adequate organ function who achieved stable disease or a partial or complete response after 4 to 6 chemotherapy cycles were randomized to sunitinib at a dose of 50 mg/day (28 days on and 14 days off) or placebo. The primary endpoint was the 6‐month progression rate. Secondary endpoints were safety, survival, change in serum vascular endothelial growth factor (VEGF)/soluble VEGF receptor‐2 (sVEGFR2), and the activity of sunitinib in patients who developed disease progression while receiving placebo. A total of 38 eligible patients per treatment arm were required to select better therapy with 90% probability (α = .05).RESULTSA total of 54 eligible patients were randomized to either the sunitinib arm (26 patients) or the placebo arm (28 patients). The median number of cycles received was 2 cycles per treatment arm. The most common grade 3 to 4 adverse events (graded according to version 3.0 of the National Cancer Institute Common Terminology Criteria for Adverse Events) among patients receiving sunitinib were thrombocytopenia, diarrhea, mucositis, fatigue, and hypertension. There were no grade 3 or 4 adverse events noted among > 5% of patients receiving placebo. The 6‐month progression rate was 72% versus 64%. The median progression‐free survival (PFS) was 2.9 months (range, 0.5 months‐32.5 months) versus 2.7 months (range, 0.8 months −65 months) for the sunitinib versus placebo arms, respectively. Patients receiving placebo were found to have no changes in their serum VEGF/sVEGFR2 levels over time. Patients treated with sunitinib had no significant change in their VEGF level, but the sVEGFR2 level significantly decreased after cycles 1 and 2 (P < .0001) and at the time of disease progression (P = .0002). A baseline VEGF level that was at or greater than the median was found to be correlated with a longer PFS. Sixteen patients who were receiving placebo received sunitinib at the time of disease progression, with the best responses being 1 partial response (6.3%), 6 cases of stable disease (37.5%), and 5 cases of progressive disease (31.3%); 4 patients were not evaluable for response. The median PFS was 3.7 months (range, 0.1 months‐22 months).CONCLUSIONSThe current multicenter study was limited by premature closure and a small sample size. Maintenance sunitinib did not appear to improve the 6‐month progression rate. Open‐label sunitinib was found to have only modest activity. The sVEGFR2 level decreased among patients receiving sunitinib. Cancer 2014;120:692–701. © 2013 American Cancer Society.
Disease Location Is Associated With Survival in Patients With Peripheral Arterial Disease
Chen, Qian , Bailey, Kent R. , Wennberg, Paul W. , Smith, Carin Y. , Kullo, Iftikhar J.

Mayo Clinic

Journal of the American Heart Association | October 22, 2013 | Volume: 2 | Issue: 5 | Pages: No page available

10.1161/jaha.113.000304 | PMID 24145740 Get It

Background We investigated whether disease location influences survival in patients with peripheral arterial disease. Methods and Results Patients (n=12 731; mean age, 67.5±12.7 years; 57.4% male) who underwent outpatient noninvasive lower extremity arterial evaluation were followed up for 5.9±3.1 years for all‐cause mortality. Peripheral arterial disease (n=8930) was defined as a resting or postexercise ankle‐brachial index ( ABI ) ≤0.90, and normal ABI (n=3 801) was defined as a resting and postexercise ABI of 1.00 to 1.30. Presence or absence of disease at the proximal location or distal location was determined on the basis of D oppler signals in leg arteries; 42% had no PD or DD , 45% had proximal (14% postexercise PD only), 30% had distal disease, 17% had both proximal and distal disease, 28% had proximal only and 14% had distal only. We performed multivariable logistic regression to identify factors associated with disease location, and C ox proportional hazard regression to assess the respective effects of proximal or distal disease on survival. Older age, male sex, diabetes, heart failure, and critical limb ischemia were associated with distal disease, whereas female sex, smoking, hypertension, dyslipidemia, coronary heart disease, cerebrovascular disease, chronic obstructive pulmonary disease, and critical limb ischemia were associated with proximal disease. Over a mean follow‐up of 5.9±3.1 years, 3039 patients (23.9%) died. After adjustment for potential confounders, the hazard ratios ( HR s) of death associated with PD only and DD only were 1.3 (1.3 to 1.4) and 1.5 (1.4 to 1.6), respectively. After additional adjustment for resting ABI , there was no significant association between proximal disease and death, whereas the association of distal disease with death remained significant ( HR , 1.2; 95% CI , 1.1 to 1.3). Conclusions In patients with peripheral arterial disease, proximal and distal disease locations were associated with distinctive risk factor and comorbidity profiles. Distal disease was associated with worse survival even after adjustment for risk factors, comorbidities, and resting ABI .
P2–086: MRS differentiates people with MCI who progress to dementia with Lewy bodies from people who progress to Alzheimer's disease
Zhang, Bing , Maroney‐Smith, Mandie, Petersen, Ronald C. , Ferman, Tanis J. , Boeve, Bradley F. , Smith, Glenn E. , Knopman, David S. , Jack, Clifford R. , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_9 | Pages: No page available

10.1016/j.jalz.2013.05.729 Get It